Introduction

Q fever is a zoonotic infection caused by *Coxiella burnetii*. Q fever may present as an acute illness with fever, pneumonia and hepatitis being the most common manifestations. After the acute illness or an asymptomatic primary infection, patients may develop a chronic focal infection that can be life threatening and require prolonged combination of antimicrobials for cure. While the treatment of acute Q fever is based on doxycycline alone, treatment of chronic Q fever is comprised of a prolonged (at least 18 months) combination of doxycycline and hydroxychloroquine. Alternatives to this regimen have rarely been based on doxycycline alone, treatment of chronic Q fever is comprised of a prolonged (at least 18 months) combination of doxycycline and hydroxychloroquine. Alternatives to this regimen have rarely been tested systematically. Furthermore, inability to use doxycycline in Q infection that can be life threatening and require prolonged combination of antimicrobials for cure. While the treatment of acute Q fever is based on doxycycline alone, treatment of chronic Q fever is comprised of a prolonged (at least 18 months) combination of doxycycline and hydroxychloroquine. Alternatives to this regimen have rarely been tested systematically. Furthermore, inability to use doxycycline in Q fever, as in cases of allergy or pregnancy poses a major challenge to the clinician. Herein we present a case of a 45 year old woman with chronic Q fever that required desensitization to doxycycline due to treatment failure with an alternative regimen.

Case presentation

A 45 year old woman presented to her primary care physician in August 2014 because of one week of fever up to 40 °C, nonproductive cough, night sweats, and vomiting. She was working as a nurse in a geriatric hospital and denied direct contact with farm animals. Her physical examination and chest X-ray were remarkable. Chest CT demonstrated soft infiltrates in the RUL. Serology for Q fever at that time showed an increase of phase I- IgG to 1600, phase II- IgM positive, Phase II- IgG positive (titer of 1:800) (Table 1). Transthoracic echocardiography showed minimal pericardial effusion and mitral valve prolapse but no regurgitation or valvular vegetations.

Treatment with doxycycline was initiated. The patient did not recall previous exposure to doxycycline. However, the first tablet caused intense itching all over her body and the second tablet caused a sensation of suffocation. She did not seek medical help but stopped taking the drug. Treatment was therefore switched to clarithromycin for 10 days, and in light of persistent cough and malaise, treatment was followed by a course of moxifloxacin for another 15 days. Nevertheless, she continued to be symptomatic with low grade fever, persistent cough, night sweats and weight loss. Due to lack of improvement, the patient was referred to an infectious diseases specialist for further work up. Serology for Q fever was sent out to the Israeli Center for Rickettsial Diseases and the values were consistent with acute C. burnetii infection: Phase I- IgM positive, Phase I- IgG negative, Phase II- IgM positive, Phase II- IgG positive (titer of 1:800) (Table 1). Transthoracic echocardiography showed minimal pericardial effusion and mitral valve prolapse but no regurgitation or valvular vegetations.

Treatment with doxycycline was initiated. The patient did not recall previous exposure to doxycycline. However, the first tablet caused intense itching all over her body and the second tablet caused a sensation of suffocation. She did not seek medical help but stopped taking the drug. Treatment was therefore switched to clarithromycin for 10 days, and in light of persistent cough and malaise, treatment was followed by a course of moxifloxacin for another 15 days. Nevertheless, she continued to be symptomatic with low grade fever, persistent cough, night sweats and weight loss. Due to lack of improvement, the patient was hospitalized in December 2014. Again, physical examination was unremarkable. Her blood count showed no leukocytosis, and platelets were in normal range. The C-reactive protein was slightly elevated and the liver enzymes were normal.

We present the case of a 45 year old woman with acute Q fever pneumonia who progressed to the chronic phase of the disease despite azithromycin therapy. A trial of doxycycline was halted because of severe allergy and she was put on clarithromycin and later moxifloxacin. Failure of both drugs required desensitization to doxycycline with escalating doses. After two-year treatment with doxycycline-hydroxychloroquine combination, complete recovery was declared. Our case highlights the option of doxycycline desensitization when an acute allergic reaction poses an obstacle to optimal treatment.

**ARTICLE INFO**

Keywords:
Q fever  
*Coxiella burnetii*  
Doxycycline  
Desensitization  
Moxifloxacin  
Clarithromycin

**ABSTRACT**

We present the case of a 45 year old woman with acute Q fever pneumonia who progressed to the chronic phase of the disease despite azithromycin therapy. A trial of doxycycline was halted because of severe allergy and she was put on clarithromycin and later moxifloxacin. Failure of both drugs required desensitization to doxycycline with escalating doses. After two-year treatment with doxycycline-hydroxychloroquine combination, complete recovery was declared. Our case highlights the option of doxycycline desensitization when an acute allergic reaction poses an obstacle to optimal treatment.
A.L. Caplunik-Pratsch et al.  
IDCases 11 (2018) 70–72

ment. The combined treatment was continued until January 2017.

A previously published protocol based on IV doxycycline administered without complications. The desensitization was performed according to our institution for doxycycline desensitization which she underwent in the meantime treatment with TMP/SMX and hydroxychloroquine was commenced. She was hospitalized at our institution for doxycycline desensitization which she underwent without complications. The desensitization was performed according to a previously published protocol based on IV doxycycline administered as slow IV pushes in escalating concentrations until after 4 h the oral dose of 100 mg is given (Table 2) [2]. After successful desensitization, doxycycline was added to the regimen of hydroxychloroquine and TMP/SMX.

With this regimen there was a fast improvement in her condition. She stopped coughing and her temperature went back to normal. Follow-up serology in February 2015 (after 1.5 months of treatment) showed a decline in phase I- IgG from 1600 to 400, phase II IgG declined from > 6400 to 3200, phase I and II IgM became negative. Under prolonged treatment with a combination of TMP/SMX, hydroxychloroquine and doxycycline, phase I and II IgG became negative. Under prolonged treatment with a combination of TMP/SMX, hydroxychloroquine and doxycycline, phase I IgG declined until it was completely undetectable after 6 months of treatment (June 2015). Phase II IgG decreased to 400. The patient felt well except for slight occasional nausea, probably as a side effect of the antimicrobial treatment. The combined treatment was continued until January 2017.

Table 1  
Chronological order of serology results and antimicrobial treatment.

| Date       | Serology                        | Treatment                                      |
|------------|--------------------------------|-----------------------------------------------|
|            | Phase I, IgM                     |                                               |
|            | Phase I, IgG                     |                                               |
|            | Phase II, IgM                    |                                               |
|            | Phase II, IgG                    |                                               |
| 19/8/2014  | positive                        | Azithromycin, 5 days                          |
| 31/08/2014 | negative                        | Doxycycline started but discontinued after one day d/t allergic reaction |
| 29/8/2014  | Positive                        | Clarithromycin, 10 days                       |
| 02/10/2014 | 1:400                           | Moxifloxacin, 15 days                         |
| 20/10/2014 | Positive                        | TMP/SMX and Hydroxychloroquine started        |
| 21/12/2014 | Negative                        | DESENSITIZATION: continued treatment with Doxycycline, TMP/SMX and Hydroxychloroquine |
| 09/12/2014 | 1:100                           |                                               |
| 28/12/2014 | negative                        |                                               |
| 15/1/2015  | borderline                       |                                               |
| 15/2/2015  | negative                        |                                               |
| 16/3/2015  | negative                        |                                               |
| 23/6/2015  | negative                        |                                               |
| 30/9/2015  | negative                        |                                               |
| January 2017 | Negative                        |                                               |
|            | Higher than 1:6400              |                                               |
|            | 1:6400                          |                                               |
|            | 1:3200                          |                                               |
|            | 1:400                           |                                               |
|            | 1:1600                          |                                               |
|            | 1:600                           |                                               |
|            | 45                              |                                               |
|            | 5                               |                                               |
|            | 135                             |                                               |
|            | 60                              |                                               |
|            | 75                              |                                               |
|            | 90                              |                                               |
|            | 105                             |                                               |
|            | 120                             |                                               |
|            | 135                             |                                               |
|            | 150                             |                                               |
|            | 165                             |                                               |
|            | 180                             |                                               |
|            | 195                             |                                               |
|            | 210                             |                                               |
|            | 240                             |                                               |

phase I- IgM was positive; Phase II IgG was > 6400. A transosophageal echocardiography (TEE) did not show vegetations.

The patient was then referred again to an ID specialist who consulted with the Immunology/Allergy Unit of our hospital. Because of previous treatment failures with alternative regimens, doxycycline desensitization was proposed. In the meantime treatment with TMP/SMX and hydroxychloroquine was commenced. She was hospitalized at our institution for doxycycline desensitization which she underwent without complications. The desensitization was performed according to a previously published protocol based on IV doxycycline administered as slow IV pushes in escalating concentrations until after 4 h the oral dose of 100 mg is given (Table 2) [2]. After successful desensitization, doxycycline was added to the regimen of hydroxychloroquine and TMP/SMX.

With this regimen there was a fast improvement in her condition. She stopped coughing and her temperature went back to normal. Follow-up serology in February 2015 (after 1.5 months of treatment) showed a decline in phase I- IgG from 1600 to 400, phase II IgG declined from > 6400 to 3200, phase I and II IgM became negative. Under prolonged treatment with a combination of TMP/SMX, hydroxychloroquine and doxycycline, phase I IgG declined until it was completely undetectable after 6 months of treatment (June 2015). Phase II IgG decreased to 400. The patient felt well except for slight occasional nausea, probably as a side effect of the antimicrobial treatment. The combined treatment was continued until January 2017.

Table 2  
Doxycycline desensitization protocol.

| Dosage (in mg) | Time (in minutes) |
|---------------|-------------------|
| 0.001         | 0                 |
| 0.002         | 15                |
| 0.005         | 30                |
| 0.01          | 45                |
| 0.02          | 60                |
| 0.05          | 75                |
| 0.1           | 90                |
| 0.2           | 105               |
| 0.5           | 120               |
| 1             | 135               |
| 2             | 150               |
| 5             | 165               |
| 10            | 180               |
| 25            | 195               |
| 55            | 210               |
| 100 oral      | 240               |

Discussion

We present a case of a patient with acute Q fever pneumonia who progressed to the chronic phase of the disease. Treatment regimens without doxycycline failed to cure the patient, therefore doxycycline desensitization was performed. In our opinion the patient can clearly be diagnosed as having developed chronic Q fever in light of the persistence of symptoms, the serological tests and the signs of pneumonia on chest CT, which can be regarded as the probable local focus. However, based on current recommendations, adding a PCR blood test, and/or FDG-PET/CT could have enhanced the diagnostic accuracy.

As Coxiella burnetii is a strictly intracellular pathogen conventional antimicrobial susceptibility testing is not feasible and assessing the in-vitro activity of different drugs is challenging as clinical trials comparing their efficacy for treatment of Q fever are complicated by two aspects: firstly, the self-limited course of acute Q fever in the majority of patients and second because of the need for prolonged therapy and follow up for the chronic localized disease. In-vitro, clarithromycin and moxifloxacin that were used as alternatives in our case have been proved to be effective [3,4]. However, only few clinical trials assessed their clinical efficacy: Gikas et al. retrospectively assessed 113 patients with acute Q fever who received treatment before the availability of serology results: time to defervescence was significantly shorter in patients treated with macroldilides than in patients who received beta-lactams (with clarithromycin performing best of the given macrolides). Time to defervescence, however, was still longer than in patients treated with doxycycline [5]. Another retrospective study from Croatia included 77 patients with acute Q fever receiving doxycycline, clarithromycin or moxifloxacin. In this study, mean time to defervescence was 2.4 days for those receiving doxycycline, 1.9 days for those receiving clarithromycin, and 2.2 days for those receiving moxifloxacin, suggesting non-inferiority of these two alternative antibiotics [6]. In both studies however there was no long term follow up regarding progression to chronic disease.

The superiority of hydroxychloroquine/doxycycline combination treatment in chronic Q fever is probably due to the fact that hydroxychloroquine renders doxycycline bactericidal to Coxiella burnetii by raising the pH in the pseudolysosomal vacuole [7]. No trials have compared their efficacy: Gikas et al. retrospectively assessed 113 patients with acute Q fever who received treatment before the availability of serology results: time to defervescence was significantly shorter in patients treated with macroldilides than in patients who received beta-lactams (with clarithromycin performing best of the given macrolides). Time to defervescence, however, was still longer than in patients treated with doxycycline [5]. Another retrospective study from Croatia included 77 patients with acute Q fever receiving doxycycline, clarithromycin or moxifloxacin. In this study, mean time to defervescence was 2.4 days for those receiving doxycycline, 1.9 days for those receiving clarithromycin, and 2.2 days for those receiving moxifloxacin, suggesting non-inferiority of these two alternative antibiotics [6]. In both studies however there was no long term follow up regarding progression to chronic disease.

The superiority of hydroxychloroquine/doxycycline combination treatment in chronic Q fever is probably due to the fact that hydroxychloroquine renders doxycycline bactericidal to Coxiella burnetii by raising the pH in the pseudolysosomal vacuole [7]. No trials have evaluated treatment regimens for persistent localized infection that do not contain doxycycline.

Desensitization should be considered for patients with an immediate type drug reaction for whom there are no available alternative treatments. There are two previous case reports of successful desensitization to doxycycline for the treatment of Q fever and Ehrlichiosis [2,8]. Data from the French Pharmacovigilance Database (FPD) suggest that
hypersensitivity reactions to tetracyclines, especially to doxycycline, are generally rare events [9]. Allergic reaction to doxycycline is a clinical diagnosis as no skin test is available today. Our patient developed pruritus and shortness of breath upon treatment with doxycycline, signs that are typical of immediate type allergic reactions, without other exposures to new drugs. The process of desensitization alters the immune response to the specific drug and results in temporary tolerance, which means that the patient can take an uninterrupted course of the medication safely. Our patient was considered an appropriate candidate for desensitization due to her type of drug reaction and the failure of alternative treatments.

In summary, our case report points out the clinical importance to consider the option of desensitization if acute allergic reactions pose an obstacle to indispensable antimicrobial treatment as it undoubtedly is the case for the treatment of chronic localized Q fever with doxycycline containing regimens.

Consent for publication

Written informed consent was obtained from the patient for publication of this case report.

Disclosure

The authors declare that they have no competing interests.

Acknowledgements

Not applicable.

References

[1] Oren I, Kraoz Z, Hadani Y, Kassis I, Zaltzman-Bershady N, Finkelstein R. An outbreak of Q fever in an urban area in Israel. Eur J Clin Microbiol Infect Dis 2005;24:338–41.
[2] Fernando SI, Hudson BJ. Rapid desensitization to doxycycline. Ann Allergy Asthma Immunol 2013;111:73–4.
[3] Maurin M, Raoult D. In vitro susceptibilities of spotted fever group rickettsiae and Coxiella burnetii to clarithromycin. Antimicrob Agents Chemother 1993;37:2633–7.
[4] Rolain JM, Maurin M, Raoult D. Bacteriostatic and bactericidal activities of moxifloxacin against Coxiella burnetii. Antimicrob Agents Chemother 2001;45:301–2.
[5] Gikas A, Kofteridis DP, Manios A, Pediaditis J, Tselentis Y. Newer macrolides as empiric treatment for acute Q fever infection. Antimicrob Agents Chemother 2001;45:2644–6.
[6] Morovic M. Q Fever pneumonia: are clarithromycin and moxifloxacin alternative treatments only? Am J Trop Med Hyg 2005;73:947–8.
[7] Raoult D, Drancourt M, Vestrin G. Bactericidal effect of doxycycline associated with lysoisomotropic agents on Coxiella burnetii in P988D1 cells. Antimicrob Agents Chemother 1990;34:1512–4.
[8] Stollings JL, Chadha SN, Paul AM, Shaver CM, Hagaman D. Doxycycline desensitization for a suspected case of ehrlichiosis. J Allergy Clin Immunol Pract 2014;2:103–4.
[9] Lebrun-Vignes B, Kreft-Jais C, Castot A, Chosidow O. Comparative analysis of adverse drug reactions to tetracyclines: results of a French national survey and review of the literature. Br J Dermatol 2012;166:1333–41.